Traditional flu vaccines face new challenges
The U.S. administration has approved the use of the first flu vaccine from Moderna that is based on mRNA technology, following promising results demonstrating its efficacy and safety. This vaccine represents a significant advancement in the field of influenza vaccines, as it has been proven effective in immunizing individuals against the virus. It is expected to enhance the immune response compared to traditional vaccines. This approval comes as part of the United States' efforts to strengthen its fight against the flu and improve seasonal vaccination strategies.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)